Polymyxin B2

Polymyxin B2

SCHEMBL29514784

CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCN)NC1=O)C(C)O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCN)NC1=O)C(C)O

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 3/20 0.98
▸ RCOR1 Q9UKL0 2/20 0.98
▸ LDHB P07195 3/20 0.42
▸ TERF2IP Q9NYB0 4/20 0.42
▸ EGFR P00533 1/20 0.40
▸ LCK P06239 1/20 0.40
▸ HKDC1 Q2TB90 1/20 0.39
▸ NPY1R P25929 1/20 0.39
▸ NPY2R P49146 1/20 0.39
▸ NPY4R P50391 1/20 0.39
▸ NPY5R Q15761 1/20 0.39
▸ PSMB5 P28074 2/20 0.39
▸ PSMB2 P49721 1/20 0.39
▸ SSTR2 P30874 3/20 0.38
▸ SSTR4 P31391 3/20 0.38
▸ SSTR5 P35346 3/20 0.38
▸ SSTR1 P30872 1/20 0.38
▸ SSTR3 P32745 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Polymyxin B2 SCHEMBL29356304 1.00 KDM1A (0.98) KDM1ARCOR1LDHBTERF2IPEGFR
SCHEMBL15507051 0.99 KDM1A (1.00) KDM1ARCOR1LDHBTERF2IPEGFR
SCHEMBL136097 0.99 KDM1A (1.00) KDM1ARCOR1LDHBTERF2IPEGFR
SCHEMBL21991628 0.99 KDM1A (1.00) KDM1ARCOR1LDHBTERF2IPEGFR
SCHEMBL7799155 0.99 KDM1A (1.00) KDM1ARCOR1LDHBTERF2IPEGFR
SCHEMBL23626629 0.99 KDM1A (1.00) KDM1ARCOR1LDHBTERF2IPEGFR
SCHEMBL19532503 0.99 KDM1A (1.00) KDM1ARCOR1LDHBTERF2IPEGFR
SCHEMBL16549195 0.99 KDM1A (1.00) KDM1ARCOR1LDHBTERF2IPEGFR
SCHEMBL18902502 0.99 KDM1A (1.00) KDM1ARCOR1LDHBTERF2IPEGFR
SCHEMBL14241069 0.99 KDM1A (1.00) KDM1ARCOR1LDHBTERF2IPEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346633-A1 MACOLACINS AND METHODS OF USE THEREOF UNIV ROCKEFELLER (US) 2025-11-13 — — US disclosed
CN-113057794-B Ophthalmic drug delivery device and method of making same 财团法人工业技术研究院 2023-03-10 — — CN disclosed
CN-114728075-A Compositions and methods relating to molecular conjugation 尹图赛利有限公司 2022-07-08 — — CN disclosed
WO-2022061132-A1 OPHTHALMIC DEVICES FOR THE TREATMENT OR AMELIORATION OF DRY EYE DISEASE, AND RELATED METHODS OF USE THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2022-03-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346633-A1 MACOLACINS AND METHODS OF USE THEREOF MACO1, MLEC, MGAM KDM1A 4175/4885RCOR1 4867/4885LDHB 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback